{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-002728","form_type":"8-K","ticker":"CLSDQ","cik":"0001539029","company_name":"Clearside Biomedical, Inc.","filed_at":"2022-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.918292+00:00","generated_at":"2026-06-27T01:58:37.982479+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Clearside Biomedical appoints Benjamin Yerxa, Ph.D. to Board of Directors","bullets":["Dr. Yerxa, CEO of Foundation Fighting Blindness and Clearside co-founder, appointed effective March 2, 2022.","Received option to purchase 30,000 shares at $1.49/share, vesting in 36 monthly installments.","Entitled to $40,000 annual retainer plus annual option grants for service as director.","His expertise expected to advance CLS-AX (axitinib) for wet AMD and SCS platform."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-002728","json":"https://secwatch.observer/filing/0000950170-22-002728.json","markdown":"https://secwatch.observer/filing/0000950170-22-002728.md","text":"https://secwatch.observer/filing/0000950170-22-002728.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1539029/000095017022002728/0000950170-22-002728-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1539029/000095017022002728/clsd-20220303.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T01:58:37.982479+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a7b2a6b54f","claim":"Benjamin Yerxa was appointed as director at Clearside Biomedical, Inc..","evidence_excerpt":"the board of directors (the “ Board ”) of Clearside Biomedical, Inc. (the “ Company ”) appointed Benjamin Yerxa to serve as a director of the Company, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1539029/000095017022002728/0000950170-22-002728-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}